Oral contraceptives and ovarian cancer

European Journal of Cancer Prevention

Volumn 8, Issue 4, 1999, Pages 297-304

  La Vecchia, C ^a,b   Franceschi, S ^c  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Epidemiology; Oral contraceptives; Ovarian cancer; Risk

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ARTICLE; CANCER PREVENTION; CANCER RISK; DISEASE ASSOCIATION; DRUG MECHANISM; FEMALE; GERM CELL TUMOR; HUMAN; ORAL CONTRACEPTION; OVARY CANCER; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

EID: 0032845062     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008469-199908000-00005     Document Type: Article

References (51)

1. Adami H-O, Bergström R, Persson I, Sparén P (1990). The incidence of ovarian cancer in Sweden, 1960-1984. Am J Epidemiol 132: 446-52.
2. Beral V, Hannaford P, Kay C (1988). Oral contraceptive use and malignancies of the genital tract. Results of the Royal College of General Practitioners' Oral Contraception Study. Lancet i: 1331-5.
3. Booth M, Beral V, Smith P (1989). Risk factors for ovarian cancer: a case-control study. Br J Cancer 60: 592-8.
4. Booth M, Beral V, Maconochie N, Carpenter L, Scott C (1992). A case-control study of benign ovarian tumours. J Epidemiol Community Health 46: 528-31.
5. Casagrande JT, Louie EW, Pike MC et al. (1979). Incessant ovulation and ovarian cancer. Lancet ii: 170-3.
6. CASH (Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development) (1987). The reduction in risk of ovarian cancer associated with oral contraceptive use. New Engl J Med 316: 650-5.
7. Cramer DW, Hutchison GB, Welch WR, Scully RE, Knapp RC (1982). Factors affecting the association of oral contraceptives and ovarian cancer. New Engl J Med 307: 1047-51.
8. dos Santos Silva I, Swerdlow AJ (1995). Recent trends in incidence of and mortality from breast, ovarian and endometrial cancers in England and Wales and their relation to changing fertility and oral contraceptive use. Br J Cancer 72: 485-92.
9. Fioretti F, La Vecchia C, Tavani A, Parazzini F (1996). Package inserts of oral contraceptives in Italy. Pharmacoepidemiol Drug Safety 5: 315-19.
10. Franceschi S, La Vecchia C, Helmrich SP, Mangioni C, Tognoni G (1982). Risk factors for epithelial ovarian cancer in Italy. Am J Epidemiol, 115: 714-19.
11. Franceschi S, Parazzini F, Negri E et al. (1991). Pooled analysis of three European case-control studies of epithelial ovarian cancer. III. Oral contraceptive use. Int J Cancer 49: 61-5.
12. Gross TP, Schlesselman JJ (1994). The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet Gynecol 83: 419-24.
13. Gross TP, Schlessclman JJ, Stadel BV, Yu W, Lee NC (1992). The risk of epithelial ovarian cancer in short-term users of oral contraceptives. Am J Epidemiol 136: 46-53.
14. Hankinson SE, Colditz GA, Hunter DJ et al. (1995). A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 76: 284-90.
15. Harlow BL, Weiss NS, Roth GJ, Chu J, Daling JR (1988). Case-control study of borderline ovarian tumors: reproductive history and exposure to exogenous female hormones. Cancer Res 48: 5849-52.
16. Harris R, Whittemore AS, Itnyre J (The Collaborative Ovarian Cancer Group) (1992). Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Am J Epidemiol 136: 1204-11.
17. Hartge P, Schiffman MH, Hoover R et al. (1989). A case-control study of epithelial ovarian cancer. Am J Obstet Gynecol 161: 10-16.
18. Hildreth NG, Kelsey JL, LiVolsi VA et al. (1981). An epidemiologic study of epithelial carcinoma of the ovary. Am J Epidemiol 114: 398-405.
19. Horn-Ross PL, Whittemore AS, Harris R, Itnyre J (the Collaborative Ovarian Cancer Group) (1992). Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. VI. Nonepithelial cancers among adults. Epidemiology 3: 490-5.
20. John EM, Whittemore AS, Harris R, Itnyre J (the Collaborative Ovarian Cancer Group) (1993). Characteristics relating to ovarian cancer risk: collaborative analysis of seven US case-control studies. Epithelial ovarian cancer in black women. J Natl Cancer Inst 85: 142-7.
21. Koper NP, Kicmeney LALM, Massuger LFAG et al. (1996). Ovarian cancer incidence (1989-1991) and mortality (1954-1993) in the Netherlands. Obstet Gynecol 88: 387-93.
22. La Vecchia C, Lucchini F, Negri E et al. (1992). Trends of cancer mortality in Europe, 1955-1989: III. Breast and genital sites. Eur J Cancer 28A: 927-98.
23. La Vecchia C, Tavani A, Franceschi S, Parazzini F (1996). Oral contraceptives and cancer. Drug Safety 14: 260-72.
24. La Vecchia C, Negri E, Levi F, Decarli A, Boyle P (1998). Cancer mortality in Europe: effects of age, cohort of birth and period of death. Eur J Cancer 34: 118-41.
25. Levi F, Gutzwiller F, Decarli A, La Vecchia C (1987). Oral contraceptive use and breast and ovarian cancer mortality in Switzerland. J Epidemiol Comm Health 41: 267-8.
26. Parazzini F, La Vecchia C, Franceschi S, Negri E, Cecchetti G (1989). Risk factors for endometrioid mucinous and serous benign ovarian cysts. Int J Cancer 18: 108-12.
27. Parazzini F, Franceschi S, La Vecchia C, Fasoli M (1991a). The epidemiology of ovarian cancer. Gynecol Oncol 43: 9-23.
28. Parazzini F, La Vecchia C, Negri E et al. (1991b). Oral contraceptives use and the risk of ovarian cancer: an Italian case-control study. Eur J Cancer 27: 594-8.
29. Parazzini F, Restelli C, La Vecchia C et al. (1991c). Risk factors for epithelial ovarian tumours of borderline malignancy. Int J Epidemiol 20: 871-7.
30. Parazzini F, La Vecchia C, Negri E, Moroni S, Villa A (1995). Risk factors for benign ovarian teratomas. Br J Cancer 71: 644-6.
31. Polychronopoulou A, Tzonou A, Hsich C et al. (1993). Reproductive variables, tobacco, ethanol, coffee and somatometry as risk factors for ovarian cancer. Int J Cancer 55: 402-7.
32. Purdie D, Green A, Bain C et al. (for the Survey of Women's Health Group) (1995). Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. Int J Cancer 62: 678-84.
33. Ramcharan S, Pellegrin FA, Ray R, Hsu JP (1981). The Walnut Creek Contraceptive Study. A Prospective Study of the Side Effects of Oral Contraceptives. NIH Publication No. 81-564, vol. iii; Bethesda, MD: National Institute of Health.
34. Risch HA, Marrett LD, Howe GR (1994). Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol 140: 585-97.
35. Risch HA, Weiss NS, Lyon JL, Daling JR, Lift JM (1983). Events of reproductive life and the incidence of epithelial ovarian cancer. Am J Epidemiol 117: 128-39.
36. Risch HA, Marrett LD, Jain M, Howe GR (1996). Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol 144: 363-72.
37. Rosenberg L, Shapiro S, Slone D et al. (1982). Epithelial ovarian cancer and combination oral contraceptives. J Am Med Assoc 247: 3210-12.
38. Rosenberg L, Palmer JR, Zauber AG et al. (1994). A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 139: 654-61.
39. Rosenblatt KA, Thomas DB, Noonan EA (The WHO Collaborative Study of Neoplasia and Steroid Contraceptives) (1992). High-dose and low-dose combined oral contraceptives: protection against epithelial ovarian cancer and the length of the protective effect. Eur J Cancer 28A: 1872-6.
40. Shu XO, Brinton LA, Gao YT, Yuan JM (1989). Population-based case-control study of ovarian cancer in Shangai. Cancer Res 49: 3670-4.
41. Simon WE, Albrecht M, Hänsel M, Dietel M, Hölzer F (1983). Cell lines derived from human ovarian carcinomas: growth stimulation by gonadotropic and steroid hormones J Natl Cancer Inst 70: 839-45.
42. Thomas DB (The WHO Collaborative Study of Neoplasia and Steroid Contraceptives) (1991). The influence of combined oral contraceptives on risk of neoplasms in developing and developed countries. Contraception 43: 695-710.
43. Tzonou A, Day NE, Trichopoulos D et al. (1984). The epidemiology of ovarian cancer in Greece: a case-control study. Eur J Cancer Clin Oncol 20: 1045-52.
44. Vessey MP, Painter R (1995). Endometrial and ovarian cancer and oral contraceptives - Findings in a large cohort study. Br J Cancer 71: 1340-2.
45. Villard-Mackintosh L, Vessey MP, Jones L (1989). The effects of oral contraceptives and parity on ovarian cancer trends in women under 55 years of age. Br J Obstet Gynecol 96: 783-8.
46. Weiss NS, Lyon JL, Liff JM, Vollmer WM, Daling JR (1981). Incidence of ovarian cancer in relation to the use of oral contraceptives. Int J Cancer 28: 669-71.
47. Westhoff C, Pike M, Vessey M (1988). Benign ovarian teratomas: a population-based case-control study. Br J Cancer 58: 93-8.
48. Whittemore AS, Harris R, Itnyre J (the Collaborative Ovarian Cancer Group) (1992). Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 136: 1184-203.
49. WHO Collaborative Study of Neoplasia and Steroid Contraceptives (1989). Epithelial ovarian cancer and combined oral contraceptives. Int J Epidemiol 18: 538-45.
50. Willett WC, Bain C, Hennekens CH, Rosner B, Speizer FE (1981). Oral contraceptives and risk of ovarian cancer. Cancer 48: 1684-7.
51. Wu ML, Whittemore AS, Paffenbarger RS Jr et al. (1988). Personal and environmental characteristics related to epithelial ovarian cancer. I. Reproductive and menstrual events and oral contraceptive use. Am J Epidemiol 128: 1216-27.